EANS-News: SYGNIS Pharma AG / SYGNIS further strengthens its patent position for AX200 for the treatment of stroke

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Patents, Copyright & Trademarks

Heidelberg (euro adhoc) - SYGNIS further strengthens its patent
position for AX200 for the treatment of stroke

Heidelberg, September 15, 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage biotech
company researching and developing innovative therapies for
neurodegenerative diseases, today announced that the European Patent
Office has given two notices regarding their intention to issue
additional AX200-patents shortly. The respective patent
applications cover the use of AX200 for the acute and chronic
stage of a stroke. These additional patents will further
strengthen SYGNIS´ patent portfolio of AX200 for the treatment of
stroke which consists of six patent families.

The claims of the patent application for the treatment of acute
stroke cover the actual use and dosage of AX200 as applied in the
current Phase II efficacy study of AX200 (AXIS 2) and as intended
to be used in clinical practice at a later stage. With a
scheduled expiry date of 2028, these claims complement the key
patent granted in Europe in 2006 and in the USA in 2009, covering
the use of AX200 for the treatment of stroke.

The claims of the second patent application cover the treatment
of patients with AX200 in the chronic stage of a stroke. They have a
scheduled expiry date of 2025 and complement SYGNIS´
IP-position in the early recovery phase following a stroke.

Dr. Frank Rathgeb, CMO of SYGNIS commented: "The granting of these
patents will considerably strengthen the protection of our
approaches for the treatment of stroke with AX200 as well as the
actual therapeutic regimen for the acute treatment. Especially
with regard to the top-line data of the AXIS 2-trial which we
expect to report towards the end of this calendar year, this
improved patent position will increase the overall value of the
AX200 project and the awareness amongst potential partners."

About AX200

AX200 is a biological molecule, developed by SYGNIS for the
treatment of neurodegenerative diseases. In the indication stroke it
is the most advanced drug candidate in SYGNIS´ product pipeline.
AX200 is an endogenous protein. As part of the body's own
protective action the production of AX200 is boosted after brain
damage. If the molecule is given as a medication it increases the
existing endogenous response to the damage. SYGNIS pursues a
multiple neurotherapeutic approach in the development of AX200 for
the treatment of neurodegenerative diseases: AX200 stops neuronal
cell death in the acute phase of the disease while at the same
time stimulating the regeneration of the already damaged CNS
through the stimulation of neurogenesis as well as
arteriogenesis and the reorganisation of neuronal networks.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,
is a specialty pharmaceutical company listed in the Prime
Standard of the Frankfurt Stock Exchange. The Company is
focused on the research and development of innovative therapies for
the treatment of disorders of the Central Nervous System. SYGNIS´
core projects are currently Acute Stroke for which SYGNIS´ lead
clinical programme is AX200, as well as the preclinical
KIBRA-project for the treatment of different forms of dementia.
All these disorders are characterized by the fact that, as the
disease progresses, nerve cells are damaged and die. Although there
is great medical demand, there are currently no or only
inadequate treatment options available. Furthermore, a key element
of the sustainable value creation of the Company is the expansion
of the product pipeline, which will be secured through its own
developments as well as in-licensing and acquisitions.

For further information please contact:
SYGNIS Pharma AG:

|Dr. Franz-Werner Haas |
|Senior Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English